PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Kollodis BioSciences, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Kollodis Enters into Distribution Agreement for MAPTrix® ECM with Cambridge Bioscience - Kollodis signs new Distribution Agreement for MAPTrix® ECM line of products in England
Kollodis Enters into Distribution Agreement for MAPTrix® ECM with Cambridge Bioscience

 

NewswireToday - /newswire/ - Malden, MA, United States, 2010/01/05 - Kollodis signs new Distribution Agreement for MAPTrix® ECM line of products in England.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Kollodis BioSciences, Inc. announced today that it has entered into an Exclusive Distribution Agreement with Cambridge Bioscience Ltd. for the distribution of Kollodis BioSciences, Inc.'s MAPTrix® ECM line of products for cell culture and related applications. The exclusive agreement provides Cambridge Bioscience with the rights to distribute Kollodis’ cell culture products in the United Kingdom and Republic of Ireland.

Cambridge Bioscience is a well established marketing partner for life science technology companies wishing to build their business in the European markets. The initial term of the appointment is two years which may be extended.

Dr. Louis M. Scarmoutzos, President & CEO of Kollodis BioSciences, Inc., stated, "MAPTrix® is an exciting business opportunity providing a unique offering that can be of great value for its clients and customers in academics and in the pharmaceutical and life sciences industries. The appointment of Cambridge Bioscience as our distributor will provide us with an extended reach into the important UK and Ireland markets."

Mike Kerins, Managing Director at Cambridge Bioscience commented, “We are delighted to be working with Kollodis on the commercialization of their highly innovative MAPTrix® technology. We see wide application for this technology in the areas of stem cell research and tissue engineering.

Among the Mussel Adhesive Protein based matrix (MAPTrix®) ECM line of products are reagents with genetically incorporated bioactive peptides (recognition peptides) that mimic the extracellular matrix (ECM) activity of collagen, fibronectin, laminin, and vitronectin proteins. The bioactive peptide mimics the extracellular matrix (ECM) protein and provides for cell attachment, spreading and growth. The mussel adhesive protein confers biocompatible adhesion to a wide variety of surfaces.

A MAPTrix® surface coating application promotes cell plating efficiency, improves morphology, and enhances cell proliferation under serum-free conditions in primary cell cultures such as hepatocytes or neural cells.

About Cambridge Bioscience Ltd

Cambridge Bioscience Ltd. is a leading distributor in the U.K. and Ireland, providing products for life science research. One of the longest established companies serving this market, Cambridge Bioscience has built a comprehensive product portfolio representing some of the world’s most innovative suppliers. With over 22 years of experience, the expertise and knowledge within the company is used in identifying and fulfilling the requirements of the research community. Additional information is available on the Company's website.

About Kollodis BioSciences, Inc.

Kollodis BioSciences, Inc. (kollodis.com) has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is developing MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix® platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications. Additional information is available on the Company's website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Kollodis BioSciences, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Kollodis Enters into Distribution Agreement for MAPTrix® ECM with Cambridge Bioscience

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sangjae Lee - Kollodis.com 
617-283-2182 lscarmoutzos[.]kollodis.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Kollodis BioSciences, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Kollodis BioSciences, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)